Results 51 to 60 of about 236,815 (335)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source

Comparative analysis of blood lymphocytes of patients with acute and chronic myeloid leukemia by surface and intracellular α1-acid glycoprotein and fibronectin

Біологічні студії, 2014
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj   +1 more source

Early Risk Prediction of Chronic Myeloid Leukemia with Protein Sequences using Machine Learning-based Meta-Ensemble [PDF]

arXiv, 2023
Leukemia, the cancer of blood cells, originates in the blood-forming cells of the bone marrow. In Chronic Myeloid Leukemia (CML) conditions, the cells partially become mature that look like normal white blood cells but do not resist infection effectively.
arxiv  

Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation [PDF]

Leukemia. 24 (2010) 460-6, 2010
Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to an adherent monocytic phenotype ...
arxiv   +1 more source

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

Molecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa, Zdenka Herudkova, Jan Hyl, Jakub Vlazny, Filip Sokol, Kvetoslava Matulova, Adam Folta, Jakub Hynst, Lucy Vojtova, Leos Kren, Martin Repko, Zdenek Racil, Jiri Mayer, Martin Culen   +13 more
wiley   +1 more source

Low expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia

Tumor Biology, 2017
Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive.
Jing-dong Zhou, Dong-ming Yao, Li Han, Gao-fei Xiao, Hong Guo, Ting-juan Zhang, Xi-xi Li, Qian Yuan, Lei Yang, Jiang Lin, Jun Qian   +10 more
doaj   +1 more source

Clinical proteomics of myeloid leukemia [PDF]

Genome Medicine, 2010
Myeloid leukemias are a heterogeneous group of diseases originating from bone marrow myeloid progenitor cells. Patients with myeloid leukemias can achieve long-term survival through targeted therapy, cure after intensive chemotherapy or short-term survival because of highly chemoresistant disease.
Rakel Brendsdal Forthun, Gry Sjøholt, Ingvild Haaland, Håkon Reikvam, Bjørn Tore Gjertsen, Øystein Bruserud, Sigrun M. Hjelle   +6 more
openaire   +3 more sources

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]

Anais Brasileiros de Dermatologia, 2017
: Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites.
Erica Rodrigues de Araujo Vasconcelos, Alexander Richard Bauk, Mayra Carrijo Rochael   +2 more
doaj   +1 more source

Myeloid leukemia after hematotoxins. [PDF]

Environmental Health Perspectives, 1996
One of the most serious consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can now be distinguished. Classic therapy-related myeloid leukemia typically occurs 5 to 7 years after exposure to alkylating agents and/or irradiation, has a myelodysplastic phase with ...
Richard A. Larson, James W. Vardiman, Michelle M. LeBeau, Janet D. Rowley   +3 more
openaire   +2 more sources